pragma.vision Technology observatory & strategic foresight

Verification register Bio, Health & Neuro

Readiness verdict

Zenbexus (iberdomide) — first CELMoD therapy

A dated reading of what is claimed, reported, and independently verified in the current evidence.

As of
2026-08-20
Revision
1
Method
v1.3.0

Current reading

Readiness band and full integer triple

AI-assisted assembly · derived results

Readiness band

Ready

Primary summary from verified readiness

Confidence
63% · fresh
Computed at
2026-08-20T10:56:05.345626+00:00
Claimed
80

Public ambition and stated capability

Reported
77

Observed practitioner reporting

Verified
69

Independently supported evidence

Gap
+11

Claimed leads verified

Evidence strength Critical

Decision

What the current evidence supports

Human editorial judgment · 2026-08-20

Track; not yet

Why
Approval is accelerated and conditional on a still-pending confirmatory trial, and the pivotal-trial toxicity profile (84.3% Grade 3/4 neutropenia, 4.9% fatal AEs, boxed warnings + REMS) is material enough that the therapy's real-world risk/benefit maturity is not yet settled even though initial efficacy data (41% vs 21% MRD-negative CR, p<.0001) is strong.
Next
Re-check at the EXCALIBER-RRMM confirmatory PFS/OS readout and at post-launch REMS/pharmacovigilance updates before upgrading the readiness classification toward full approval status.

Constraints

Blockers

No named blocker is present in the current public projection.

Evidence summary

Derived counts

AI-assisted assembly

Total
5
Tier 1
0
Tier 2
2
Tier 3
3
Supports
3
Contradicts
1
Context
1
Latest observed
2026-08-14

Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.

Publication record

Revisions

Initial public reading

  1. 2026-08-17 Reading moved from ready to ready.

Your opinion

Tell us anything.

What works, what doesn't, what's missing — especially about our watches, lenses, and the register itself. Anonymous is fine; leave an email if you'd like a reply.